aTyr Pharma to Host Conference Call and Webcast of First

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
40
aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018

SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results on Monday, May 14, 2018 before the open of the U.S. financial markets. Company management will host a conference call and webcast on Monday, May 14, 2018 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss the results and provide a corporate update.

Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 8255679.

The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts . An audio replay will be available for at least 90 days following the event. 

About aTyr Pharma

aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 candidate is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com .

IMMEDIATE RELEASE Contact: Mark Johnson Sr. Director, Investor Relations mjohnson@atyrpharma.com 858-223-1163

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 4

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 8

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 3

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 2

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 6

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 5

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 9

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackRock's Strong Performance Lifts Market Spirits

Updated Category News Views 62

BlackRock's Earnings Impact Future Market Trends As investors eagerly glance at the market, recent trends suggest a positive shift, particularly with BlackRock, Inc. reporting remarkable third-quarter earnings. The upbeat results have lifted not only the company’s profile but also the sentiments across various sectors. Market Overview In recent trading sessions, U.S....

Continue Reading
Endo Unveils I Got Somebody Campaign for Peyronie's Disease

Updated Category News Views 648

Endo Launches Awareness Campaign for Peyronie’s Disease Endo, Inc. (OTCQX: NDOI) has recently introduced a compelling initiative titled I Got Somebody. This campaign is designed to encourage men to confront their feelings of embarrassment around Peyronie's disease (PD) and to have open discussions about this condition which affects many. The company aims to empower men...

Continue Reading
Investigation Launched into Aehr Test Systems for Investors' Losses

Updated Category News Views 218

Investigation into Aehr Test Systems, Inc. Focused on Investor Protection The Law Offices of Frank R. Cruz are actively investigating Aehr Test Systems, Inc. (NASDAQ: AEHR) in light of significant concerns raised regarding the company’s adherence to federal securities laws. This investigation comes as a response to alarming financial disclosures made public by the...

Continue Reading
SeaStar Medical Advances adult AKI Treatment with Stanford

Updated Category News Views 69

SeaStar Medical Welcomes Stanford Medicine's Enrollment in AKI Trial SeaStar Medical Holding Corporation (NASDAQ: ICU) is excited to announce that Stanford Medicine will begin actively enrolling subjects in its pivotal trial focused on Adult Acute Kidney Injury (AKI). This collaboration emphasizes the company’s mission to enhance treatment options for patients...

Continue Reading
Exciting Updates on Class A Shares for Investors and Stakeholders

Updated Category News Views 163

Important Distribution Announcement for Class A Shareholders In a recent announcement, Real Estate Split Corp. (TSX: RS) has excitedly shared plans to distribute dividends to Class A shareholders. This distribution not only signifies growth but also represents the company's commitment to providing value to its investors. Key Dates for the Upcoming Distribution For...

Continue Reading